Aligos Therapeutics: Analyst Initiates Buy Rating Due to Promising HBV Treatment and Pipeline Growth

Aligos Therapeutics has initiated a new Buy rating due to its lead candidate ALG-000184 showing promising results in treating chronic hepatitis B virus (HBV). The drug has achieved significant reductions in HBV DNA and key biomarkers, making it a potential new standard-of-care for chronic HBV suppression. Aligos Therapeutics' pipeline, including ALG-055009, a thyroid hormone receptor-beta agonist, also has promising Phase 2a data in metabolic dysfunction-associated steatohepatitis (MASH). The company's strategic positioning and upcoming clinical milestones support a positive outlook for its stock.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) has initiated dosing in its Phase 2 B-SUPREME study of ALG-000184 for chronic hepatitis B virus (HBV) infection treatment. The randomized, double-blind study will enroll 200 untreated subjects over 48 weeks, comparing ALG-000184 monotherapy to tenofovir disoproxil fumarate, a current standard of care [1].

The primary endpoints of the study will focus on HBV DNA levels, with interim data expected in 2026 and topline results anticipated in 2027. The study will also evaluate safety, pharmacokinetics, and various biomarkers. The involvement of prominent hepatology experts like Dr. Nezam Afdhal lends credibility to the program [1].

Aligos Therapeutics has previously demonstrated promising results with ALG-000184 in Phase 1 studies, showing sustained reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg [1]. The company's strategic positioning and upcoming clinical milestones support a positive outlook for its stock.

References:
[1] https://www.stocktitan.net/news/ALGS/aligos-therapeutics-announces-first-subject-dosed-in-the-phase-2-b-nmn01hu2r2jc.html